, penicillin 100 000 units l and streptomycin 100 mg l -1 ; pH at 7.
The culture medium for LoVo
The standard medium recommended by the source laboratory was Hams F12 or DMEM with 10% FCS, L-glutamine 2 mM l -1 , penicillin 100 000 units l -1 and streptomycin 100 mg l -1
.
In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines
The culture medium for SW620 The standard medium recommended by the source laboratory was Leibovitz L15 medium with 10% FCS, L-glutamine 2 mM l -1 , penicillin 100 000 units l -1 and streptomycin 100 mg l -1 .
ECCM-culture medium for HUVEC M199 medium, 20% FCS, NaHCO 3 , glutamine, heparin, penicillin and streptomycin; pH 7.2 to 7.3; filtered 17 .
Method for culturing the cancer cell lines
The cancer cell lines (Hep-G2, SW620 and LoVo) were supplied in a cryotube frozen in liquid nitrogen. The cryotube was left at room temperature for 1 min, then transferred to 37°C waterbath for 2 min. The cells in the cryotube were thawed, decanted into a sterile universal with 10 ml of medium (at 4°C) and centrifuged at 90 g for 7 min. The cell pellet was re-suspended with pre-warmed culture medium (Dulbecco's modified Eagle's medium, DMEM), cultured in a vented 25 mm 2 flask and incubated with 5% carbon dioxide humid atmosphere at 37°C. At 90% confluence, the cells were subcultured by discarding the old medium, washing with phosphate-buffered saline (PBS) less Ca 2+ /Mg 2+ and then trypsinizing the monolayer with trypsin-EDTA (× 1), for 5-10 min, until the cells were detached. The cells were then suspended in culture medium, centrifuged at 90 g for 5 min and then subcultured in 96-well plates, seeded at 1 × 10 4 cells per well, and incubated overnight at 37°C at 5% carbon dioxide (CO 2 ) and humidity. The cultures were examined 24 h before starting the radioisotope experiment (Leibovitz et al, 1976; Drewinko et al, 1976; Knowles et al, 1980) . The mean cell culture doubling times for Hep-G2 and LoVo was 19 h (range 18-20) and for SW620 was 20 h (range 19-21). Full aseptic precautions were used with the cell cultures.
Method for culturing HUVEC
A fresh umbilical cord was collected from the labour ward in a sterile container with 200 ml of M199 medium and 10% NBCS (new born calf serum). Ethical approval from the Obstetric Unit was obtained. The cord was examined for any damage or clamp marks, selecting a suitable 20 cm segment for culture. The two ends of the umbilical vein were cannulated with a size 16 or 18 F tube and the tubes were secured with silk ties. The vein was flushed with PBS solution (less Ca 2+ /Mg 2+ ), to remove any blood clots, and to detect any leaks. Collagenase 0.1% solution (15 ml) was then injected into the vein and it was incubated at 37°C for 5 min. The collagenase solution was then decanted into a sterile container. An equal volume of M199-20% NBCS was added to neutralize the collagenase, and the suspended cells were centrifuged at 300 g for 5 min. The cells in the pellet were resuspended with endothelial cell culture medium (ECCM), cultured in vented flasks (25 mm 2 ) and incubated at 37°C with 5% CO 2 humid atmosphere. At 24 h the cultures were washed with 5 ml of M199 medium to remove dead cells and red blood cells, and then the cells were fed with fresh ECCM every 48 h and incubated at 37°C with 5% CO 2 and humidity. When a 90% confluent cell monolayer was reached, the cells were subcultured by discarding the old medium, washing the monolayer with PBS (less Ca 2+ /Mg 2+ ) and then trypsinizing the culture with trypsin-EDTA (× 1) for 3-5 min at 37°C, until cells were detached. The enzyme was then partially neutralized by the addition of 20% NBCS in M199 medium, and the cell suspension was centrifuged at 300 g for 5 min. Cell counts and viability were determined by trypan blue exclusion using a haemocytometer. The cells in the pellet were resuspended in 100 µl of ECGS (endothelial cell growth supplement) and culture medium (ECCM). The cells were subcultured in 96-well plates, seeded at 1 × 10 4 per well and incubated at 37°C with 5% CO 2 and humidity, and left overnight to settle. The cultures were examined 24 h before starting the radioisotope experiment (Jaffe et al, 1973; Jaffe, 1987) . The mean cell culture doubling time for HUVEC was 20.5 h (range 19-22). 
Radioisotopes

General method
Each of the cell lines were subcultured in 96-well plates; cells were seeded at 1 × 10 4 cells per well. The cell cultures were allowed to grow overnight in a humidified incubator with an atmosphere of 5% CO 2 at 37°C. At 24 h (zero hour), the old medium was discarded and replaced with control or radioisotope culture medium according to the appropriate concentration and radioactivity, and the cultures were then allowed to grow for a further period of up to 48 h. Lipiodol was emulsified with diatrizoate (urografin) into an aqueous-based emulsion, similar to the standard clinical use of urografin prior to the arterial administration of Lipiodol. The cell cultures were treated as follows:
1. 100 µl medium in each of the control wells (first control), with culture medium only. 2. 100 µl cold-Lipiodol medium (4%) in each of the Lipiodol control wells (second control). 3. 100 µl of plain 131 I 40 µCi ml -1 in each of the radioactive control wells (third control). 4. 100 µl of the 131 I-Lipiodol 10 µCi ml -1 emulsion in each of the I 131 low-dose wells (equivalent to 4% Lipiodol). 5. 100 µl of the 131 I-Lipiodol 20 µCi ml -1 emulsion in each of the I 131 medium-dose wells (= 4% Lipiodol). This is equivalent to the radio-therapeutic clinical dose. 6. 100 µl of the 131 I-Lipiodol 40 µCi ml -1 emulsion in each of the I 131 high-dose wells (equivalent to 4% Lipiodol).
The cultures were incubated at 37°C with 5% CO 2 for 48 h in a special shielded (radioisotope) room under full radiation protection control. The experiment was repeated three times with four sets of plates for each cell line, each containing six identical wells for each test dose of radioactivity. At the end of the incubation period, the control and radioactive culture media were discarded appropriately and the cell monolayers were washed with PBS solution three times. One set of the plates was then processed for cell density and viability using the sulphorhodamine B (SRB) assay (Skehan et al, 1990) . Another set of the plates was processed for measurement of cellular radioactivity using a gamma scintillation counter (Pharmacia, 1470 Wizard). The 96-well plates were put into the gamma scintillation counter using the appropriately selected mode of radioactivity for 131 I after calibration, and a computerized readout was obtained. Cell viability and counts were further assessed with the standard trypan blue exclusion method using the haemocytometer. After trypsinization, the cells were suspended in medium, and the cell count was calculated for each well. Nine readings were calculated per well and the mean value was obtained. The total cell count was calculated by multiplying the mean result by the total volume in which the cells were suspended. Light and electron microscopy examinations were also used to assess cytotoxicity and uptake of radioactivity.
Method for the sulphorhodamine B (SRB) test
This test was used to measure cell density after treatment, by using protein analysis. At the end of the experiment (exposure to radioisotopes or controls), the medium was discarded and the wells were rinsed with PBS and the cells were then exposed to 100 µl of cold 10% wv trichloroacetic acid for 1 h at 4°C. The plates were then washed with water and air dried. The SRB assay was commenced by dissolving 0.4% wv SRB in 1% acetic acid and adding 100 µl to each well to stain the fixed cells for 30 min. The dye was then removed and immediately rinsed with 1% acetic acid four times and then air dried. The assay reading was commenced by solubilizing the bound dye with 100 µl 10 mM (0.121 g 100 ml -1 ) Tris base, pH 10.5, for 15 min on a gyratory shaker. The cell density was calculated for each culture using a 96-well plate reader at 490 nm (Skehan et al, 1990 ).
RESULTS
Using previously described method, Lipiodol uptake by all the cancer cell lines and by the endothelial cells was demonstrated on light and electron microscopy as early as 3 h (Al-Mufti et al, 1996) . In this study, 131 I-Lipiodol was also demonstrated within the cancers cells and the benign endothelial cells as early as 6 h. Lipiodol alone as a control (without 131 I) had no effect on the cell growth or viability when compared to the controls, and was therefore not cytotoxic to any of the cell lines used in this study. At early stages of exposure, there were no cytotoxic effects seen as expected.
131 I-Lipiodol was found to be highly cytotoxic against all the three malignant cell lines (Hep-G2, LoVo and SW620) at the low-, medium-and high-dose range (P = 0.0001, Figure 1 ). The cytotoxicity effects of 131 I-Lipiodol increased with increasing doses of radioactivity, with optimal toxicity being achieved with the high-dose (40 µCi ml Table 4 ) but did reduce the rate of cell growth (cytostatic effect). The percentage of endothelial cell viability remained high (87-93%) after exposure to the three different doses of 131 I-Lipiodol, compared to 96% cell viability in the control cultures.
131 I alone did not have any cytotoxic effect against any of the cell lines used (malignant and non-malignant cells), even at high dosage (40 µCi ml -1 ) despite the cells being in direct contact with the radioiodine (Figures 1 and 2) . In fact the cell growth and count of the control endothelial cells was slightly higher after exposure to 131 I alone, and all the cultures (malignant and non-malignant) maintained a high percentage of cell viability (97-98%).
Light and electron microscopy confirmed the uptake of Lipiodol in the form of cytoplasmic membrane-bound vesicles in all the cell lines (malignant and non-malignant) as illustrated in Figure 3A . Electron microscopy also confirmed the uptake of 131 I-Lipiodol by all the cells and the cytotoxic effects of 131 I-Lipiodol on the cancer cell lines ( Figure 3B ). There was 100% cell death at 48 h, leaving cell shadows and cytoskeletons of dead cancer cells still containing 131 I-Lipiodol vesicles ( Figure 3B ). In contrast, electron microscopic study of the non-malignant control endothelial cells confirmed the high percentage of cell viability (percentage of viable cells 80-85%) at 48 h of exposure to 131 I-Lipiodol, in spite of its uptake by the endothelial cells, as illustrated in Figure 4 . Sulphorhodamine B test and gamma scintillation counting (Table 5 ) correlated well with the cell growth curves, cell viability assays and electron microscopy. All the cell lines showed high cellular radioactivity following exposure to 131 I-Lipiodol, but the (Tables 1-4 ). This confirmed that Lipiodol was essential for transporting 131 I into the cells to achieve its preferential cytotoxicity effects in the malignant cells (i.e. intracellular radiotherapy).
DISCUSSION
This study confirms that the uptake of Lipiodol is not specific to cancer cell lines, as the non-malignant endothelial cells take up Lipiodol as well. However, 131 I-Lipiodol is selectively and highly cytotoxic against all the cancer cell lines but not against the benign endothelial cells. Although the mechanism of Lipiodol uptake is poorly understood, this study confirms our previous reports that Lipiodol is taken up and is retained in the form of cytoplasmic membrane-bound vesicles (Al-Mufti et al, 1995) . Quantification methods using computer-assisted image analysis of the uptake of Lipiodol by the malignant and the non-malignant cell lines (Al-Mufti et al, 1996) have revealed that cancer cell lines, unlike non-malignant cells, are unable to expel Lipiodol. This may further enhance the cytotoxic effect of 131 I-Lipiodol in cancer cells. Lipiodol alone does not appear to have any cytotoxic effect against any of the cell lines studied. This confirms the clinical observations seen in many in vivo studies of Lipiodol-targeted therapies of liver cancers. It is noteworthy that, in this study, 131 I alone without the Lipiodol has no cytotoxic effect against any of the cell lines tested. This is in spite of the cell cultures being exposed directly to a high and comparable dose of 131 I radioactivity in their culture medium (extracellular radiation). This is the first study to show the importance of using Lipiodol to deliver 131 I, by virtue of its ability to deliver the isotope inside the cancer cells (intracellular radiotherapy), even if in membrane-bound vesicles. There is no separation of the 131 I from Lipiodol during the process of uptake by the cancer cells, as Lipiodol is a naturally iodinated oil compound, with an iodine content of 38-40%. 131 ILipiodol shows cytotoxic effects against the cancer cell lines even when the radioactive dose is very small, a quarter of the radioactivity of the 131 I alone.
The morphological changes observed with light and electron microscopy, following 131 I-Lipiodol administration, confirmed intracellular 131 I-Lipiodol vesicles inducing acute cell death of cancer cells, with maximum effect seen at 24 and 48 h, with little effects at the early stages of exposure (3 and 6 h) as expected. However, the effects on the non-malignant endothelial cells were only cytostatic, giving a reduction in the rate of cell growth, but a high percentage viable cells. This mechanism may operate in vivo when Lipiodol-targeted therapies are used. The long-term apoptotic effects of 131 I-Lipiodol on the control endothelial cells were not evaluated further in this study.
As Lipiodol is a naturally iodized oil with a higher density than the aqueous culture media, one could argue that by leaving the culture media incubated for 48 h inside the incubator, the 131 I-Lipiodol component of the emulsion could then separate and sink into the bottom of the wells and would come into intimate contact with cell monolayers at the base of the wells. However, it is unlikely that this had any significant effect on the results in this study for three reasons. Diatrizoate (urografin) was used to emulsify the Lipiodol (as it is commonly used clinically prior to the arterial administration, which would maintain the 131 I-Lipiodol in its suspended form much longer), together with the use of human endothelial cells as benign control cells and the use of much smaller doses of 131 I-Lipiodol to compare to that of 131 I alone (down to a quarter of the radioactive dose of 131 I). If the 131 I-Lipiodol were to sink down to the bottom of the wells, then one would expect that not only the cancer cells, but all the endothelial cells, to be killed because of the intimate contact with a high dose of radioactivity. There was a significant cytotoxic effect seen with the use of even a low dose of 131 I-Lipiodol (0.01 µCi µl -1
), compared to a much higher dose of radioactivity with 131 I alone (0.04 µCi µl -1 ), which had no cytotoxic effect. The use of the radioactive form of Lipiodol as a potentially effective treatment for patients with hepatocellular carcinoma and some colorectal hepatic metastases is supported by the effective localization and retention of Lipiodol by human hepatocellular and colorectal metastatic cancers in vitro. The results of 131 I-Lipiodol cytotoxicity in Hep-G2, LoVo and SW620 in this study indicate that 131 I-Lipiodol is highly cytotoxic to such tumours that show good uptake of Lipiodol, and that the radiation lethal dose can be as low as 0.01 µCi µl -1 in cell cultures, with a steep dose-response relationship. Lipiodol-targeted radiotherapy would have a limited effect against tumours that show poor Lipiodol uptake. Hepatocellular carcinoma and metastatic colorectal cancers have been regarded as resistant to radiotherapy, but this study has shown that these tumours may be sensitive to intracellular radiotherapy with 131 I-Lipiodol. This is particularly significant, since highly effective cytotoxic dosages of 131 I-Lipiodol can be administered intra-arterially quite safely in patients with these liver cancers with minimal cytotoxicity to the normal liver . The only limiting factor for Lipiodol-targeted radiotherapy, as seen in the clinical trials, is the variability of the in vivo uptake of Lipiodol by cancer cells. This is dependent on the intra-arterial delivery of Lipiodol to the cancer. If the tumour uptake of Lipiodol can be improved, then better cytotoxic effects of Lipiodol-targeted radiotherapy should be achieved. Future clinical studies should be directed towards improving the in vivo uptake of Lipiodol, for example by combining this form of targeted therapy with vasoactive agents such as angiotensin.
In conclusion, in vitro cytotoxicity assay of 131 I-Lipiodol revealed it to be cytotoxic against cells taken from human hepatocellular carcinoma and colorectal metastatic cancers but not to benign endothelial cells. This was related to the selective uptake and retention of Lipiodol by the cancer cell lines, with evidence of intra-cytoplasmic accumulation of 131 I-Lipiodol (intracellular radiation). Equivalent or higher doses of radioactivity delivered to the cells in the absence of Lipiodol (i.e. extracellular radiation) had no toxic effect.
